Call for Special Issue Papers:
Delivery of Antisense RNA Therapeutics:
Turning Negative Results into a Positive Development

Deadline for Manuscript Submission: February 1, 2020

Guest Editors: Michela Denti; *University of Trento*; Wouter Eilers; *University of Reading*
Executive Editor: Graham Parker; *Wayne State University*

The number of novel potential RNA-based antisense therapeutics is rapidly increasing. However, efficient delivery to target tissues is still the main factor which limits their translation into the clinic. Though many groups in academia and industry are working towards the development of methods to improve antisense delivery to overcome this limitation, there are very few coordinated efforts to learn from the experience of other investigators by sharing “negative” results. These data often do not get published in scientific journals or even presented at scientific meetings, but could greatly facilitate progress in the field. To encourage the dissemination of these results, ***Nucleic Acid Therapeutics*** is looking for original research paper submissions to be published in a special issue dedicated to “negative results.”

The issue will focus on the development of novel systems, chemistries and conjugates aimed at improving the delivery of RNA-based therapeutics. Research papers based on results obtained in all model systems will be considered, but in particular, we are looking for submissions related to the following:

- Delivery strategies which lack efficacy or involve excessive toxicity
- Data on novel delivery strategies that are contrary to previously published work
- Delivery approaches that work in vitro but showed no efficacy in vivo.
- Identification of factors that explain discrepancies in results between different laboratories

Please contact Prof. Michela Denti (michela.denti@unitn.it), Dr. Wouter Eilers (w.eilers@reading.ac.uk), or Prof. Graham Parker (gparker@med.wayne.edu) if you have questions or are interested in submitting work for publication in this Special Issue. Submissions will undergo the normal ***Nucleic Acid Therapeutics*** peer review process. To learn more about the journal and submission guidelines, visit our Information for Authors website at www.liebertpub.com/nat

Submit your paper for peer review online:
<http://mc.manuscriptcentral.com/nucleicacidtherapeut>